infocusdec25

In recent years, a concerning trend has emerged in the clinical research industry. Some sponsors and Contract Research Organizations (CROs) are attempting to extend site payments to quarterly schedules and withholding a percentage of payments until the completion of a study. This financial strategy impacts clinical research sites significantly, and understanding these implications is crucial for making informed business decisions. David Vulcano, Honorary President of the Society for Clinical Research Sites, highlights this issue, emphasizing that while many sponsors and CROs offer timely resources to sites for their studies, others are testing the waters to see if sites will accept delayed payments. Unfortunately, some sites are yielding to this pressure. This situation is troubling because sites incur costs as they conduct research, and delayed payments can result in strained operations and decreased study performance. Impact of Quarterly Payments Under typical monthly payment terms, sites receive compensation for work done in a specific month by the following month, maintaining a steady cash flow. However, with quarterly payments, sites must wait several months before receiving payment for services rendered, which can extend the accounts receivable period from an average of 45 days to 137 days. This delay could jeopardize a site’s ability to maintain smooth operations, as funds that could be immediately reinvested into ongoing work are instead left sitting in a sponsor or CRO’s bank account, accruing interest for them. The Holdback Conundrum In addition to the delay created by quarterly payments, some sponsors and CROs implement a holdback policy, where a portion of the site’s earned money is withheld until the end of the study. This amount, often around 10%, prevents sites from utilizing their full resources during crucial times of study execution. The holdback approach means sites may be forced to navigate studies without adequate cash flow, thereby impacting the quality and efficacy of the research conducted. Financial Impacts of These Payment Terms Both quarterly payments and holdbacks bear significant financial impact. As stated in our case study, quarterly payments could lead to financial resources of an estimated $100,000 disappearing due to inflation over the course of the study. Holdbacks, when compounded over time, further increase this financial erosion, with sites potentially losing out on over $169,000 in our case study. This results in resources that were earned by the site and, if paid timely, would have supported continued study operations but they simply vanished from solely due to the unfavorable payment terms. Strategies to Combat Financial Strains Financial literacy, specifically in areas like Excel’s Present Value and Future Value formulas, can assist sites to better understand the negative impact these payment terms have on their study resources.  However, even with employing cost-of-living adjustments and interest clauses on the delayed payments, it still does not compensate for the loss of adequate cash flow during the study.  In other words, even if the site is made whole in the end, inadequate cash flow is still an under-resourcing of the study.  The Bigger Picture Ultimately, this is not merely a matter of budget and terms but speaks to the broader topic of study and site optimization. Studies thrive when sites are financially supported promptly, which ensures resources are focused on the research itself rather than on survival tactics. Collaboration between sponsors, CROs, and sites with equitable and timely payment terms serves the best interest of all parties and promotes the ultimate goal of advancing clinical research. While understanding the temptation to employ such financial strategies, he emphasizes the importance of openness, collaborative negotiation, and fairness in agreements. With mutual respect and understanding of these financial dynamics, all stakeholders can better ensure the success and integrity of clinical research studies. Payment terms should align with the principle of supporting research sites—you must pay when it’s earned and in full. By addressing these financial issues, the clinical research community can work together to create a sustainable, thriving ecosystem that benefits researchers, sponsors, and, ultimately, patients worldwide.

This year's SCRS Global Site Solutions Summit celebrated the people and organizations driving clinical research forward. From groundbreaking operational solutions to transformative leadership and measurable impact on patient outcomes, the award recipients represent the best of what collaboration, innovation, and commitment can achieve. These are the organizations and leaders setting the standard for what's possible...

For over a decade, Cognizant’s Shared Investigator Platform (SIP) has transformed global clinical research, evolving from a bold vision into a trusted solution that connects thousands of sponsors, sites, and investigators. Today, SIP continues to streamline collaboration, accelerate trials, and enhance transparency to deliver better patient outcomes.

Clinical research continues to evolve toward greater connectivity and efficiency, yet study startup remains one of the most complex and time-consuming stages of a trial. Disjointed systems and communication gaps between sponsors, CROs, and research sites often lead to avoidable delays. To address these challenges, Advarra...

“It’s incredibly frustrating […] we want technology that actually improves their job”. This was shared in a recent Site Listening Session, but it’s a sentiment I’m sure many can relate to. When tools that are intended to support and accelerate are delivered without their users in mind, it’s a recipe for failure. For sites, every redundant training, missed integration opportunity, and feature that doesn’t quite work as it should, ticks away at the time that could be better spent with patients.

The landscape of oncology clinical research is rapidly evolving with the emergence of radiopharmaceutical therapies, also known as radioligand therapy (RLT). These innovative treatments represent a precision medicine approach that uses targeted radiation to treat cancer with a goal of minimizing damage to healthy tissue. However,